Posts for Ticker ‘VRTX’

Top 10 Analyst Upgrades, Downgrades, Initiations (DVN, XOM, HES, ITW, LEA, NFLX, PALM, PARD, SPWRA, VRTX)

These are this morning’s top ten analyst upgrades, downgrades, and initiations seen from Wall Street research calls:

Devon Energy (NYSE: DVN) Raised to Outperform at Wells Fargo.
Exxon Mobil Corp. (NYSE: XOM) Raised to Overweight at Barclays.
Hess Corporation (NYSE: HES) Raised to Buy at UBS.
Illinois Tool Works (NYSE: ITW) Raised to Buy at UBS.
Lear Corp. (NYSE: LEA) Started as Overweight at JPMorgan.
Netflix Inc. (NASDAQ: NFLX) Started as Buy at Collins Stewart.
Palm Inc. (NASDAQ: PALM) Raised to Buy at Kaufman.
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) Cut to Market Perform at Rodman & Renshaw.
Sunpower Corporation (NASDAQ: SPWRA) Cut to Neutral at Piper Jaffray; Cut to Market Perform at FBR Capital Markets.
Vertex Pharmaceuticals (NASDAQ: VRTX) Cut to Neutral at Merriman Curhan Ford.

You can join our open email distribution list to hear more news on key analyst calls, top day trader alerts, Buffett and other investment gurus, IPOs, secondary offerings, mergers and more.

JON C. OGG

Posted on: November 17, 2009 – 8:01 am in Pre-Market Activity, Trading Alert, , , , , , , , , ,

Today’s Best Market Rumors (9/29/2009) (AMD)(GOOG)(AMGN)

newspaperUpdated throughout the day.

Update:  Xerox (XRX) may find that IBM (IBM) or HP (HPQ) outbid it for ACS (ACS)  (Barron’s)

Update:  Apple (AAPL) may be working on a touchscreen remote for an upcoming TV product.  (The Boy Genius Report)

Update: Sequenom (SQNM) is recovering some losses, perhaps due to rumors it may be sold (TheStreet)

Warner Music (WMG) may be near a licensing deal with Google’s (GOOG) YouTube. (WSJ)

Hedge fund manager John Paulson may try to merge CIT (CIT) with IndyMac Federal Bank (NYPost)

Cytokinetics (CYTK) continues to rise despite denying rumorsthat it may be bought by Amgen (AMGN) (DJ Newswires).

AMD (AMD) could be at riskfor bankruptcy. (MarketWatch)

Alexion Pharmaceuticals (ALXN) and Vertex Pharmaceuticals (VRTX) may be acquisition targets.  (The Deal)

Douglas A. McIntyre

Posted on: September 29, 2009 – 9:13 am in Rumors, , , , , , , , , , , , , ,

Biotech Business Daily (BIIB, VRTX, ALNY, STEM)

Here are some of the top stories affecting key drug and biotech stocks this Friday.  We also have links through to more detailed coverage and analysis at BioHealthInvestor.com:

Biogen Idec Inc. (Nasdaq: BIIB) kicks off the earnings season for the large biotech companies next week. We have a full earnings preview with current expectations and the bias.  A decline in analyst sentiment for the stock might set up the company for a slight earnings surprise, on the back of recent price increases for its high-profile multiple sclerosis drug Avonex.

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) this morning said it will sell its rights to milestone payments tied to its hepatitis C drug telaprevir in Europe, a possible sign that the launch of the drug with partner Johnson & Johnson (NYSE: JNJ) for 2011 may be on track.

Also, see our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 10, 2009 – 10:07 am in Biotech, , , ,

The Biotech Industry Prepares For A Wave Of Consolidation

biotech

Underscoring just how much big pharma will depend on biotech acquisitions for future revenue, an analysis published by Evaluate Pharma today suggests half of the top 100 drugs worldwide by 2014 – and all of the top six — will be biotechs.

Three in the top six – the anticancer drugs Avastin, Rituxan and Herceptin, — are all made by Roche, which recently moved to acquire even more biotech drugs with its plans to acquire Genentech. Read More »

Posted on: June 17, 2009 – 6:36 pm in Biotech, Mergers and Buy Outs, , , , , , ,

Top 10 Analyst Upgrades & Downgrades (ALTR, XLNX, BMRN, FWLT, PALM, VRTX, EIX, MGM, POM, TIF)

These are the top 10 analyst calls we have seen this Wednesday morning with about two hours until the market opens:

  • Altera (ALTR) and Xilinx (XLNX) Raised to Overweight at Global Crown.
  • Biomarin Pharma    (BMRN) Raised to Buy at Citigroup.
  • Foster Wheeler (FWLT) Raised to Buy at Jefferies.
  • Palm (PALM) Raised to Buy at Piper Jaffray.
  • Vertex Pharm (VRTX) Raised to Accumulate at ThinkEquity.
  • Edison (EIX) Cut to Market Perform at Wachovia.
  • MGM Mirage (MGM) Cut to Hold at KeyBanc.
  • Pepco Holdings (POM) was downgraded at both Barclays and at Wachovia.
  • Tiffany (TIF) target cut by over 60% to $21.00 at HSBC.

JON C. OGG
March 4, 2009

Posted on: March 4, 2009 – 7:53 am in Analyst Calls, , , , , , , , , ,

Top 10 Early Bird Analyst Upgrades & Downgrades (BBBY, BTI, PAG, VRTX, MT, STD, CRXL, FMCN, MR, OWW)

These are the ten early bird analyst upgrades and downgrades we have seen early this morning with two and a half hours until the market opens:

  • Bed Bath & Beyond Raised (BBBY) Raised to Neutral from Sell at Goldman Sachs.
  • British American Tobacco (BTI) Raised to Buy at Goldman Sachs.
  • Penske Automotive (PAG) Raised to Buy at Goldman Sachs.
  • Vertex Pharmaceuticals (VRTX) Started as Buy at piper Jaffray.
  • Arcelor Mittal (MT) Cut to Sell from Buy at5 Citigroup.
  • Banco Santander (STD) Cut to Underweight at JPMorgan.
  • Crucell (CRXL) Cut to Hold at ING.
  • Focus Media (FMCN) Downgraded at Citigroup and Goldman Sachs (likely others as well).
  • Mindray Medical International (MR) Downgraded at Citigroup and Goldman Sachs.
  • Orbitz Worldwide (OWW) Cut to Sell at Goldman Sachs.

Jon C. Ogg
November 12, 2008

Posted on: November 12, 2008 – 7:06 am in Analyst Calls, , , , , , , , , ,

Status on Companies Raising Cash (ORA, TCBI, VRTX, OTTR)

We have seen three issues so far since yesterday’s close to sell shares of stock and one offering still pending on the calendar for the week.  We have seen filings out of Ormat Technologies Inc. (NYSE: ORA), Texas Capital Bancshares, Inc. (NASDAQ: TCBI), and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).  We are also still waiting for pricing from Otter Tail Corp. (NASDAQ: OTTR) on its secondary offering.

Read More »

Posted on: September 18, 2008 – 8:18 am in Secondary Offering, , , ,

Top Pre-Market Analyst Downgrades (ADLR, MDRX, CRDN, CAG, IFF, MFE, TWX, VRTX, VOD, WWWW)

These are some of the top analyst downgrades and negative calls we are seeing this Wednesday morning:

  • Adolor (ADLR) Cut to Neutral at Piper Jaffray.
  • Allscripts (MDRX) Cut to Neutral at Piper Jaffray.
  • Ceradyne (CRDN) Cut to Underperform at Wachovia.
  • ConAgra (CAG) Cut to Neutral at JPMorgan.
  • International Flavors (IFF) Started as Underweight at Lehman.
  • McAfee (MFE) Cut to Underperform at FBR.
  • Time Warner Inc. (TWX) Cut to Market Perform at Bernstein.
  • Vertex (VRTX) Cut to Perform at Oppenheimer.
  • Vodafone plc (VOD) Cut to Neutral at Credit Suisse.
  • Web.com (WWWW) Cut to Market Perform at FBR.

Jon C. Ogg
September 3, 2008

Posted on: September 3, 2008 – 7:06 am in Analyst Calls, , , , , , , , , ,

Top Early Analyst Upgrades (CIEN, DF, GENZ, LPX, M, TAP, NOV, OC, VRTX)

These are some of the preliminary upgrades or positive research calls seen out of Wall Street analysts this Monday morning in early morning hours:

  • Ciena (NASDAQ: CIEN) raised to Market Perform at JMP Securities.
  • Dean Foods (NYSE: DF) Raised to Overweight at JPMorgan.
  • Genzyme (NASDAQ: GENZ) Raised to Buy from Hold at Citigroup.
  • Louisiana Pacific (NYSE: LPX) Raised To Sector Perform from Underperform at RBC.
  • Macy’s (NYSE: M) Raised to Neutral from Underweight at JPMorgan.
  • Molson Coors (NYSE: TAP) Raised to Buy from Hold at Deutsche Bank.
  • National Oilwell Varco (NYSE: NOV) Raised to Buy at Banc of America.
  • Owens Corning (NYSE: OC) Raised to Outperform at Morgan Keegan.
  • Vertex Pharma (NASDAQ: VRTX) Started as Overweight at Thomas Weisel.

Jon C. Ogg
July 14, 2008

Posted on: July 14, 2008 – 6:27 am in Analyst Calls, , , , , , , , ,

Biotech Busine$$ Daily (BNT, TEVA, BPAX, NCST, RPRX, VRTX)

Bentley Pharmaceuticals Inc. (NYSE: BNT) will be purchased by Teva Pharmaceutical Industries (NASDAQ: TEVA) for $360 million. Bentley shareholders will receive $15 per share and an undisclosed amount of shares in CPEX Pharmaceuticals, a drug-delivery Bentley spin-off. Bentley sells about 130 products in Spain and the transaction will allow Teva to meet its strategic Spain target. Bentley is up 15% to $15.70 on a 52-week range of $8.06 to $15.89. Teva is up marginally, almost 2% to $46.81 on the announcement. Their 52-week range is $35.90 to $50.00.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced Friday they are to begin Phase III late stage studies for their “Viagra for Women” treatment, LibiGel, which attempts to remedy a loss of libido in women. Shares are not stimulated, down by $0.55, a 12% drop, to $4.13. The 52-week range is $2.05 to $8.00.

Nucryst Pharmaceuticals Corporation (NASDAQ: NCST) up over by over $0.60, a whopping 60% jump, to $1.64 in mid-day trading on new news. Friday, the stock dropped $0.50 to a new 52-week low. This volatile infection and inflammation biotech company has a 52-week range of $1.01 to $1.85.

Repros Therapeutics (NASDAQ: RPRX) reported some interim safety results from its ongoing One-Year open label study of its Proellex(R) for the indicated treatment of uterine fibroids.  Its shares are up 2.4% today.  We just covered this one in our weekly "10 Stocks Under $10" subscriber newsletter this morning ahead of the news.  It’s still under that $10.00 threshold, for now.

Vertex Pharmaceuticals Inc. (VRTX) and their hepatitis C competitor, Schering-Plough, released clinical data on their respective drugs today. Schering-Plough’s drug, boceprevir, did not stack up to Vertex’s previously presented similar clinical data, hinting that Schering-Plough may not be as big as a competitor in the market as previously expected. Paired with positive results on Vertex’s drug, the stock is up almost 20% to $22.34 in mid-day trading. The 52-week range is $19.99 to $22.61.

Rachel Lopez
March 31, 2008

Posted on: March 31, 2008 – 11:23 am in Biotech, , , , , ,

The 52-Week Low Club (VRTX)(NT)(DY)

Dycom Industries (DY) Company lowers forecast. Falls to $15 from 52-week high of $34.13.

Nortel Networks (NT) Sel-off at the end of the day. No news. Falls to $10.28 from 2-week high of $31.79.

Tapestry Pharmaceuticals (TPPH) Company cuts 65% of work-force move toward Chapter 11. Falls to $.04 from 52-week high of $2.07.

Nxstage Medical (NXTM) Bigger than expected quarterly loss. Sells off to $8.01 from 52-week high of $15.61.

Neurometrix (NURO) Company has loss in quarter. Falls to $4.04 from 52-week high of $12.10.

Vertex Pharmaceuticals (VRTX) Costs running higher than expected. Drops to $16.04 from 52-week high of $41.42.

Douglas A. McIntyre

Posted on: February 12, 2008 – 4:56 pm in HI/LOW, , , , , ,

The 52-Week Low Club (ARUN)(UBS)(IAR)

Idearc (NYSE: IAR) Sell off from bad earnings continues. Falls to $8.55 from 52-week high of $38.

R H Donnelley (NYSE: RHD) Shares downgraded. Sells off to $17.33 from 52-week high of $84.49.

Infineon Technologies (NYSE: IFX) German tech still coming down because of bad numbers. Hits low of $8.01 from 52-week high of $18.74.

UBS AG (NYSE: UBS) Tough time to be an international bank. Sells off to $36.55 from 52-week high of $66.26.

Aruba Networks (NASD: ARUN) Poor quarter takes stock down. Falls to $4.81 from 52-week high of $23.85.

UTI Worldwide (NASD: UTIW) Planning big staff cuts. Drops to $16.80 from 52-week high of $32.

Cephalon (NASD: CEPH) Biotech gets downgraded. Sells down to $58.23 from 52-week high of $84.83.

Vertex Pharmaceuticals (NASD: VRTX) No news. Falls to $17.59 from 52-week high of $41.42.

Douglas A. McIntyre

Posted on: February 8, 2008 – 4:02 pm in HI/LOW, , , , , , , ,

52-Week Low Club (ALO, AEIS, CAMD, DGII, DLX, EBAY, IPCS, MRCY, MTSC, PRS, RJF, THQI, VRTX)

Yesterday saw many stocks hitting 52-week lows and then a sharp recovery with a low to high swing of more than 500 DJIA points.  Here are some of the stocks that hit 52-week lows today:

  • Alpharma (ALO) fell over 2% to a new 52-week low.
  • Advanced Energy (AEIS) continued its slide after disappointing earnings this week.
  • California Micro Devices Corp. (CAMD) slid 6% and even more intraday two days after earnings.
  • Digi International (DGII) fell over 10% after earnings.
  • Deluxe Corp. (DLX) didn’t look so deluxe today after a near 15% drop in earnings and a "raised guidance" that was more in-line with estimates.
  • eBay (EBAY) earnings guidance (and somewhat from the Meg Whitman departure) along with some late downgrades contributed to eBay’s new 52-week lows.
  • iPCS (IPCS) saw another tumble today.  Guess who is a Sprint reseller and guess which cellular company is under fire and announced store closures and third part closures? This looks like the Boulevard of Broken Dreams.
  • Mercury Computer Systems (MRCY) was one of the biggest percentages losers with a 30+% drop after yesterday’s earnings. This manufacturer of computer and software for embedded systems might want to change their name to Mercy Systems.
  • MTS Systems (MTSC) saw a sharp drop of roughly 15% after its earnings and "reaffirmed guidance" failed to impress.
  • Primus Guaranty Ltd. (PRS) is now down nearly two-thirds from highs, although it appears that it isn’t closing on 52-week lows even after an almost 10% drop.  Guess who sells credit swaps for their living?
  • Raymond James (RJF) saw close to a 10% drop after yesterday’s numbers.
  • THQ inc. (THQI) showed not all game makers are equal after it has write-offs from title discontinuations with almost a 30% price drop today.
  • Vertex Pharma (VRTX) spent much of the day at 52-week lows although it clawed back above the $19.13 low at the end of the trading session.  This was at a 2-year low yesterday on a hepatitis-C trial timing issue.  Citigroup downgraded it today.

Jon C. Ogg
January 24, 2008

Posted on: January 24, 2008 – 4:01 pm in HI/LOW, , , , , , , , , , , , ,

Pre-Market Stock News (January 23, 2008)

We are full fledged into earnings season now, so most news coverage will point to the current earnings environment and guidance.  There are of course drug developments and other contracts awards.  Below is a snapshot of some of the key data we saw affecting shares in pre-market trading:

  • Abbott Laboratories (ABT) $0.93 EPS versus $0.92 estimate; sees Q1 EPS $0.61 to $0.63 versus $0.65 estimates and sees 2008 EPS $3.20 to $3.25 versus $3.22 estimate.
  • Advanced Energy Industries Inc. (NASDAQ: AEIS) traded down over 10% after after it lowered guidance.
  • Air Products (APD) $1.16 EPS vs $1.13 estimates. 
  • Apple Inc. (AAPL) trading down 10% after it posted $1.76 EPS on $9.6 Billion revenues; Estimates were $1.62 EPS on revenues of $9.47 Billion; Guidance for next quarter is $0.94 EPS and revenues $6.8 Billion versus estimates of $1.09 EPS on $6.98 Billion in revenues.
  • Baidu.com (BIDU) announces the formal launch of its Japanese language search engine run by its Japanese subsidiary.
  • CheckPoint Software (CHKP) trading up almost 5% after $0.46 EPS versus $0.45 est.; Revenues $206.7M vs. $202.3M est.;
  • CNH Global (CNH) $0.50 EPS versus $0.60 estimate.
  • Coach (COH) $0.69 EPS vs $0.68 estimate; noted weak mall traffic and decline in average transaction size.
  • EntreMed (ENMD) is starting its Phase II study with its MKC-1 cell cycle inhibitor in ovarian cancer and advanced endometrial cancer.
  • Ethan Allen (ETH) posted $0.70 EPS versus $0.68 estimate.
  • Foster Wheeler (FWLT) trades ex-split to reflect a 2 for 1 stock split.
  • General Dynamics (GD) $1.42 EPS vs. $1.41 estimate; sees 2008 EPS $5.55 to $5.65 versus $5.73 estimate.
  • HOKU Scientific Inc. (HOKU) traded down 10% after earnings beat but guidance was deemed light.
  • INX (INXI) awarded Department of Defense contract to provide up to $21 million in support  of a Cisco Systems network pact.
  • Martek Biosciences (MATK) noted a December publication showed its DHA may help in late-onset Alzheimer’s, although NIH study results will be in 2010.
  • Parametric (PMTC) $0.26 EPS vs. $0.23 estimate; sees next quarter $0.24 to $0.28 vs. $0.26 estimate; sees 2008 EPS $1.17 to $1.27 vs. $1.16 estimate (revenue in-line).
  • Praxair (PX) $0.98 EPS vs $0.97 estimate.
  • Qualcomm (QCOM) expanded relationship with Motorola for chipsets into certain UMTS 3G handsets in 2008 and 2009.
  • RLI Corp. (RLI) $1.22 EPS versus $1.05 estimate.
  • Rockwell Automation (ROK) $1.04 EPS vs. $1.01 estimates; guides 200 EPS $4.25 to $4.45 versus $4.38 estimate.
  • Southwest Airlines (LUV) $0.12 EPS vs. $0.10 estimate ; reigned in 2008 growth plans to 4%-5% capacity.
  • Texas Instruments Inc. (TXN) has posted earnings of $0.54 EPS and revenues of $3.56 Billion; analysts pegged at $0.52 EPS on $3.58 Billion in revenues; sees Next quarter $0.43 to $0.49 EPS on revenues of $3.27 to $3.55 Billion versus estimates of $0.45 EPS on $3.41 Billion in revenues.
  • TJX Companies (TJX) was Jim Cramer’s retail pick on CNBC’s MAD MONEY last night.
  • United Tech (UTX) $1.08 EPS vs. $1.06 estimate; sees 2008 $4.65 to $4.85 versus $4.85 estimate.
  • Vertex Pharmaceuticals (VRTX) will begin Phase III evaluation of telaprevir for its lead investigational hepatitis C protease inhibitor.
  • WellPoint (WLP) $1.51 EPS versus $1.51 estimate.
  • Werner Enterprises (WERN) $0.28 EPS vs. $0.28 estimate.

Jon C. Ogg
January 23, 2008

Posted on: January 23, 2008 – 7:58 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , , , , ,

Top 10 Pre-Market Analyst Calls (ADCT, ADSK, BSX, EL, FFIV, PCZ, TLAB, GTS, VRTX)

These are not at all the only analyst calls that 247WallSt.com is looking at today in an active negative market, but these are 10 of the more influential calls that may stand out in an otherwise cautious or negative market:

  • ADC Telecom (NASDAQ: ADCT) raised to Outperform at Morgan Keegan.
  • Autodesk (NASDAQ: ADSK) cut to Hold from Buy at Jefferies.
  • Boston Scientific (NYSE: BSX) raised to BUY from Neutral at Banc of America.
  • Estee Lauder (NYSE: EL) raised to Neutral from Sell at UBS.
  • F5 Networks (NASDAQ: FFIV) cut to Hold from Buy at Jefferies.
  • Intel Corp. (NASDAQ: INTC) upgraded to Equal Weight from Underweight at Morgan Stanley; estimates lowered at Goldman Sachs (and likely many more).
  • Petro Canada (NYSE: PCZ) downgraded to Neutral from outperform at Credit Suisse.
  • Tellabs (NASDAQ: TLAB) raised to Buy from Neutral at UBS (large call option buying recently).
  • Triple S management (NYSE: GTS) started after quiet period: Outperform at Credit Suisse, Outperform at Oppenheimer, and Neutral at UBS.
  • Vertex (NASDAQ: VRTX) raised to Buy from Neutral at Banc of America.

Jon C. Ogg
January 16, 2008

Posted on: January 16, 2008 – 8:07 am in Analyst Calls, , , , , , , , ,

Top 10 Pre-Market Analyst Calls (AAI, AMR, BIDU, RATE, FSLR, FWLT, DNA, PCG, TOT, VRTX)

It might not be fair to only break out 10 analyst calls from the myriad of calls out there, because there are dozens to hundreds of changes daily.  Here are the key calls that 24/7 Wall St. is looking at today, besides the Cisco calls:

  • AirTran (AAI) downgraded to Neutral from Buy at UBS.
  • AMR Corp. (AMR) downgraded to Sell from Neutral at UBS.
  • Baidu.com (BIDU) downgraded to Sector Perform from outperform at RBC Capital Markets; stock down 0.5%.
  • Bankrate (RATE) downgraded at both RBC and at CIBC; stock indicated down $2 pre-market.
  • First Solar (FSLR) raised to Outperform at CIBC; stock up 20+% pre-market after earnings.
  • Foster Wheeler (FWLT) raised to Buy at Citigroup; stock up 3% pre-market.
  • Genentech (DNA) added to Goldman Sachs’ Americas Conviction Buy List, but no change to $102 target; stock indicated up almost 1%.
  • PG&E (PCG) raised to Buy at Jefferies.
  • Total SA (TOT) raised to Overweight at J.P.Morgan.
  • Vertex Pharma (VRTX) raised to Buy at Goldman Sachs; stock up 1.3% pre-market.

There are many other analyst calls not mentioned that will be having an impact on share prices, as always.

Jon C. Ogg
November 8, 2007

Posted on: November 8, 2007 – 8:13 am in Analyst Calls, , , , , , , , , ,

The 52-Week Low Club

Fremont General (FMT) Mortgage company debt rating cut. Falls to $1.81 from 52-week high of $17.30.

Valeant Pharmaceuticals (VRX) Drops on downgrade. Drops to $10.35 from $18.82.

Nordstrom (JWN) Retailers keep hurting. Drops to $33.71 from 52-week high of $59.70.

Merrill Lynch (MER) CEO gone. Big losses. Drops to $53.86 from 52-week high of $98.68.

Citigroup (C) CEO gone. Bigger loses. Drops to $35 from 52-week high of $57.

Novacea (NOVC) Drug trial blows up. Falls to $2.21 from 52-week high of $17.25.

Vertex Pharmaceuticals (VRTX) Problem with one of its drugs. Downgraded by analyst. Falls to $22.92 from 52-week high of $45.38.

Douglas A. McIntyre

Posted on: November 5, 2007 – 4:41 pm in HI/LOW, , , , , , ,

Vertex Options Active Ahead of Data Presentation

Vertex (VRTX-NASDAQ) is seeing quite a bit of trading today ahead of a data presentation tomorrow.  This one may have been very active all on its own, but since Dendreon (DNDN-NASDAQ) made its exponential move traders and chat rooms keep placing biotech bets on what they hope is "the next Dendreon." Unfortunately we do not have the super-fresh short interest data, but the short interest rose to 10.44 million shares in MARCH from 8.95 million in February.  There has been a lot of safety concerns, so be sure to keep both sides of the story in mind.

Read More »

Posted on: April 13, 2007 – 10:53 am in Biotech, , , , , , ,